非小细胞肺癌脑膜转移治疗进展

Progression of treatment for leptomeningeal metastases from non-small cell lung cancer

脑膜转移是非小细胞肺癌(NSCLC)的一种少见转移方式,一旦发生,疾病进展迅速,预后极差。随着对脑膜转移认识的加深,NSCLC脑膜转移的报道和研究逐渐增多。NSCLC脑膜转移的常规治疗方法如系统化疗、全脑放疗及鞘内化疗等疗效均不佳。随着分子靶向药物以及近年来的免疫靶向药物在NSCLC中的广泛应用,使得NSCLC脑膜转移这棘手的问题有了新的解决方案,本文就NSCLC脑膜转移治疗的最新进展进行综述。

Leptomeningeal metastases (LM) is a rare metastatic form of non-small cell lung cancer (NSCLC),with rapid progression and poor prognosis.With the deepening understanding of LM,the reports and studies of LM from NSCLC are increasing year by year.Conventional treatments for LM of NSCLC such as systemic chemotherapy,whole-brain radiotherapy (WBRT) and intrathecal (IT) chemotherapy show very limited clinical efficacy.In recent years,new solutions have been provided to the intractable problem of LM from NSCLC,as a result of widespread using of molecular targeted drugs and immune-targeted drugs.This paper reviews the progression of treatment in NSCLC with LM.